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Abstract
Background One of the most prevalent microvascular complications for patients with diabetes is diabetic retinopathy (DR)
associated with increased retinal endothelial blood vessel formation. Treatments to reduce vascularisation in the retinal endothe-
lium are linked to improved sight in patients with DR. Recently, we have demonstrated the novel protective role of the artificial
sweetener, sucralose, and the sweet taste receptor, T1R3, in the pulmonary endothelium to reduce vascular leak. In the present
study, we examined the role of sucralose and sweet taste receptors on vasculogenic processes (proliferation, migration, adhesion
and tube formation) in a cell model of the retinal endothelium.
Methods We exposed human retinal microvascular endothelial cells (RMVEC) to VEGF as an in vitro model of DR in the
presence and absence of T1R3 agonist sucralose.
Results In RMVEC, we observed increased VEGF-induced cell proliferation, migration, adhesion and tube formation, which
was significantly attenuated by exposure to the artificial sweetener sucralose. Following siRNA knockdown of the sweet taste
receptor, T1R3, but not T1R2, the protective effect of sucralose onVEGF-induced RMVEC vasculogenic processes was blocked.
We further demonstrate that sucralose attenuates VEGF-induced Akt phosphorylation to protect the retinal microvasculature.
Conclusion These studies are the first to demonstrate a protective effect of an artificial sweetener, through the sweet taste receptor
T1R3, on VEGF-induced vasculogenesis in a retinal microvascular endothelial cell line.
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Introduction
Worldwide, there are currently 425 million people estimated
to suffer from type 1 and 2 diabetes, which results in a yearly
healthcare expenditure of 727 billion USD. By 2045, the num-
ber of sufferers is predicted to increase to 693 million, which
will further increase the economic burden of the disease [1].
One of the most common and debilitating complications as-
sociated with diabetes is the development of diabetic eye
disease associated with diabetic retinopathy (DR), diabetic
macular edema and glaucoma [1]. Over 90% of patients with
type 1 diabetes and around 60% of patients with type 2 dia-
betes will suffer from a level of DR ranging from blurred
vision to complete vision loss [2]. Given the increasing inci-
dence of diabetes, there is thus a significant need to under-
stand the mechanisms which regulate DR, with the aim of
developing effective therapeutic agents for the complication.
Endothelial cell injury is a hallmark of the microvascular
complications observed due to chronic hyperglycaemia in di-
abetes. Indeed, small improvements in glycosylated-
haemoglobin directly correlate with a significantly reduced
risk of developing DR [3]. Hyperglycaemia increases meta-
bolic disruption, inflammation and hypoxia in patients with
diabetes, associated with the pathophysiology of DR [2]. DR,
characterised by retinal lesions, results in morphological
changes and increases in vascular permeability of the retinal
microvasculature [4]. In non-proliferative retinopathy, this
permeability causes macular edema which, over time, leads
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to capillary widening and degeneration of the retina whereas
in proliferative retinopathy, there is excessive formation of
blood vessels (vascularisation) around the optic disk; this ab-
errant neovascularisation is a major contributor to vision loss
and has been attributed to hyperglycaemia-induced increase in
local vitreous vascular endothelial growth factor (VEGF)
levels in patients with diabetes [5–8]. Indeed, current treat-
ment for patients with non-proliferative DR utilises anti-
VEGF agents to reduce macular edema and improve out-
comes for patients [4, 9]. However, there are concerns regard-
ing the safety of anti-VEGF agents over the long term, with a
small number of cases indicating side-effects such as an in-
creased risk of neurodegeneration for the remaining healthy
retina [10, 11]. There is thus a need to investigate potential
alternatives to current anti-VEGF agents to improve outcomes
for patients with DR.
We have previously demonstrated a role for the commonly-
consumed artificial sweetener, sucralose, in attenuating
VEGF-induced vascular leak in the pulmonary endothelium
[12]. These studies indicate that, through binding to the sweet
taste receptor T1R3, sucralose tightens the microvascular en-
dothelium and protects the barrier against leak from several
agonists including the bacterial endotoxin LPS. Whilst these
studies indicate a protective effect of the sweet taste sensing
pathway in reducing leak at the pulmonary microvasculature,
a role for artificial sweeteners in regulating the retinal endo-
thelium has not been previously studied.
Sweet taste sensing is mediated by the sweet taste receptors
T1R2 and T1R3 which form a heterodimer; however, T1R3 is
also able to form a homodimer [13]. These G protein coupled
receptors (GPCRs) are stimulated by low concentrations of
acutely sweet molecules such as artificial sweeteners (<
1 mM) or exceedingly high concentrations of glucose (>
300 mM) [14]. We previously demonstrated that sucralose
regulates expression and phosphorylation of key signalling
molecules such as p110α-PI3K, MLC2 and Src in the pulmo-
nary endothelium [12]. Interestingly, these signalling mole-
cules are all linked to processes associated with neovascular-
isation, including endothelial cell migration, adhesion, con-
traction and tube formation [15–17]. Therefore, we
hypothesised that T1R2 and T1R3 signalling, activated by
sucralose, would have an effect on vasculogenic potential of
the retinal endothelium.
In the present study we investigate, for the first time, the
role of the sweet taste receptor in regulating the retinal en-
dothelium. We demonstrate that activation of the sweet taste
receptor, with the artificial sweetener sucralose, attenuates
VEGF-induced leak across the retinal endothelial barrier.
We further demonstrate that VEGF mediates excessive cell
migration, adhesion, proliferation and tube formation in a
retinal microvascular endothelial cell line which is blocked
by sucralose. Interestingly, the protective effect of sucralose
is mediated through the sweet taste receptor T1R3 but not
T1R2. Finally, we demonstrate a role for Akt as a key sig-
nalling molecule downstream of T1R3 which regulates the
protective effect of sucralose. Our studies show that sweet
taste sensing through T1R3 plays a significant role in aber-
rant vascularisation processes which are seen in diabetes and
highlights a potential anti-VEGF therapeutic agent for pa-
tients with DR.
Methods
Cell lines, reagents and ethics
Human retina (RMVEC) and lung (LMVEC) microvascular
endothelial cells were purchased from Cell Systems
(Kirkland, WA) and ATCC (Teddington, UK) respectively.
RMVEC and LMVEC were cultured in vascular cell media
supplemented with culture boost or endothelial cell BBE kit,
respectively. Endothelial cells were used between passage 2
and 9 and maintained the traditional endothelial cell charac-
teristics of von Willebrand factor and vascular endothelial
(VE)-cadherin expression, uptake of acetylated LDL, and pos-
itive staining for the lectin Griffonia simplicifolia.
TRIzol, SuperscriptII and recombinant human VEGF pro-
tein were purchased from ThermoFisher (Paisley, UK).
siRNA and DharmaFECT™ reagent were obtained from
Dharmacon (Cambridge, UK). Antibodies directed against
T1R2, T1R3, VEGFR2 (Flk-1), phosphorylated (Ser473) and
total Akt1/2, and actin were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Antibodies were selected
from validation studies (https://scicrunch.org/resources).
Matrigel Basement Membrane Matrix was obtained from
BD Biosciences (Oxford, UK). All other reagents were
purchased from Sigma Aldrich (Dorset, UK).
All experimental protocols were approved by the
Departmental Research Ethics Panel at Anglia Ruskin
University prior to start.
Transient transfection
RMVEC were transiently transfected with T1R2 or T1R3
SMARTpool siGENOME siRNA duplexes (300 nM), or
non-specific, scrambled duplexes, using the Dharmafect™ re-
agent 4, as per the manufacturer’s guidelines. At 42 h follow-
ing transfection, cells were exposed to sucralose (0.1 mM) in
the presence or absence of zinc sulphate (0.7 mM), VEGF
(100 ng/ml) or SC79 (10 μM) for 6 h. H2O was used as a
vehicle for all treatments except SC79, where ethanol was
used. Confirmation of knockdown was performed using RT-
PCR and Western blotting analysis of mRNA and protein
expression respectively.
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RT-PCR
Total RNAs were extracted from LMVEC and RMVEC using
the TRIzol reagent as per the manufacturer’s instructions. RNA
was purified using the acid phenol/chloroform system and re-
verse transcribed using SuperScriptII. T1R2 and T1R3 tran-
scripts were measured with human β-actin primers (forward
primer CACCAACTGGGACGACAT; reverse primer
ACAGCCTGGATAGCAACG) used as the house-keeping
gene as described previously [18]. Expression of the Tas1r2
and Tas1r3 gene was measured using specific intron-spanning
primers (T1R2: forward primer AATGTCCAGCCGGT
GCTCTA, reverse primer CATCGCTGATGGCGCTGTA;
T1R3: forward primer TTCCCCCAGTACGTGAAGAC, re-
verse primer CAGAGAACGTCTGGTGGTGA). Relative gene
expression level was analysed, for each sample, using the ΔCt
method where ΔCt = (CtTas1r − Ctβ-actin) corresponding to the
detected threshold cycles for the target gene andβ-actin control.
Western blotting
LMVEC and RMVEC were lysed with RIPA buffer, resus-
pended in Laemmli buffer (50 μg) and subjected to immuno-
blot analysis. Immunoblot analyses were performed on 10%
SDS-PAGE using primary antibodies specific to T1R2, T1R3,
phosphorylated Akt1/2 (AktS473), total Akt1/2 andβ-actin at a
dilution of 1:1000, except actin (1:5000), and secondary anti-
body at dilutions of 1:5000. Densitometry was performed
using gel analysis software on ImageJ.
Whole cell ELISA
RMVEC were transiently transfected with siRNA for 42 h,
followed by exposure to sucralose and VEGF for a further 6 h.
Cells were then rinsed once with DPBS and fixed using 1%
paraformaldehyde at room temperature for 10 min.Whole cell
ELISA was then performed as previously described [12, 19]
using antibodies specific to the extracellular domain of T1R2
(H-90, αα 201-390), T1R3 (G-2, αα 320-499) and VEGFR2
(Flk-1, Q-20, αα unspecified), and fluorescent-conjugated
secondary antibodies measured at 1 s exposure time using a
florescent plate reader (Victor, Perkin Elmer).
Endothelial monolayer permeability
Endothelial monolayer permeability was assessed using the
FITC-dextran permeability assay and validated with TER
(EVOM2; World Precision Instruments, Herts, UK). For anal-
ysis of monolayer permeability, RMVEC were transiently
transfected with siRNA for 42 h on collagen-coated
Transwell filters followed by exposure to sucralose, VEGF
and zinc sulphate. Addition of treatments was made at the
same time and permeability was measured at 6 h following
treatment. FITC-conjugated to 40 kDa dextran was added to
media in the upper chamber of the Transwell filter, allowed to
equilibrate for 360 s at 37 °C, and a sample (100 μl) of media
from the lower chamber was collected and analysed at 488 nm
using a fluorescent plate reader (Victor, Perkin Elmer).
Permeability (%) was calculated by fluorescence accumulated
in the lower chamber divided by fluorescence in the upper
chamber, multiplied by 100.
Cell viability assay
RMVEC were transiently transfected with siRNA for 42 h,
followed by exposure to sucralose for a further 6 h. Viability
was assessed using the Cell Counting Kit-8 (CCK-8) as per
the manufacturer’s guidelines with absorbance read at 450 nm
using a microplate reader (Tecan Sunrise). Viability was cal-
culated as % normalised to vehicle.
Cell proliferation assay
RMVEC were transiently transfected with siRNA for 24 h,
and then quiesced in media with 1% FBS for a further 18 h.
Cells were exposed to sucralose, VEGF, zinc sulphate and
SC79, prepared in media with 1% FBS, for 6 h and counted
using a haemocytometer.
Cell migration assay
RMVEC were transiently transfected with siRNA for 42 h,
and scratched using a pipette tip and immediately treated with
sucralose, VEGF, zinc sulphate and SC79 for a further 6 h.
Cell migration was monitored at 2 h time intervals following
the initial scratch and images were captured at × 10 magnifi-
cation using a Zoe™ Cell Imager (BioRad). Cell migration
was assessed using the MiToBo analyser software in Image J
as previously described [20], with an average was assessed
from 2 wells to represent an n of 1.
Cell adhesion assay
RMVEC were transiently transfected with siRNA for 46 h,
and then replated and immediately exposed to sucralose,
VEGF, zinc sulphate and SC79 for a further 2 h. Cells were
then rinsed once with DPBS and the CCK-8 kit was used (as
described in ‘Cell viability assay’) to quantify adherent cells.
In vitro tube formation
Transfected RMVEC were plated directly onto Matrigel™-
coated wells for 42 h at 37 °C. Cells were then exposed to
sucralose, VEGF, zinc sulphate and SC79 for a further 6 h.
Images of tube formation were captured at × 10 magnification
using a Zoe™ Cell Imager (BioRad). The number of joints
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and tubes were calculated by using the Angiogenesis Analyser
software in Image J as previously described [20]. An average
from two wells was assessed to represent an n of 1.
Statistical analysis
The experimental number is presented in the legend for each
experiment. For two groups, the variance in data sets was
analysed using the Mann–Whitney test followed by the appro-
priate t test. For three or more groups, variance was assessed by
using Bartlett’s test with data sets not reaching significance stud-
ied by Kruskal–Wallis test followed by Dunn’s test. For all other
data sets, differences among the means were tested for signifi-
cance in all experiments by ANOVAwith Tukey’s range signif-
icance difference test. Significance was reached when p < 0.05.
Values are presented as mean ± standard error mean (S.E.M.)
Results
Expression of the sweet taste receptors, T1R2
and T1R3, in a human retinal microvascular
endothelial cell line
The sweet taste receptors, T1R2 and T1R3, form a heterodi-
meric complex (T1R2/T1R3) or T1R3 forms a homodimeric
complex (T1R3/T1R3) for sweet taste sensing [13]. We have
previously demonstrated mRNA and protein expression of
T1R3 in the pulmonary endothelium, at levels similar to that
of the small intestine [12]. Here we demonstrate that mRNA
and protein expression levels of both T1R2 and T1R3 in
RMVEC were comparable to expression in pulmonary endo-
thelial cells (LMVEC) (Fig. 1a, b). T1R2 and T1R3 are G
protein coupled receptors which function at the plasma mem-
brane [13] therefore we next assessed localisation of the recep-
tors to the cell surface. Using extracellular antibodies and
whole cell ELISA, expression of both T1R2 and T1R3 was
demonstrated at the cell surface of RMVEC (Fig. 1c). To con-
firm specificity of primers and antibodies, siRNA knockdown
of each receptor was performed. The expression of mRNA,
whole cell and cell surface protein was significantly reduced,
to a similar degree, following knockdown of T1R2 and T1R3
(Fig. 1a–c). These studies demonstrate, for the first time, that
the sweet taste receptors, T1R2 and T1R3, are expressed in a
human retinal microvascular endothelial cell model.
Artificial sweetener sucralose attenuates
VEGF-induced vasculogenic processes in a retinal
microvascular endothelial cell model
We next sought to establish whether activation of T1R2 and
T1R3, by low concentrations of acutely sweet molecules [21],
exhibited an effect on retinal endothelial cell function. As
sucralose did not exert any effect on RMVEC viability
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Fig. 1 Expression of the sweet taste receptors, T1R2 and T1R3, in retinal
microvascular endothelial cells. mRNA (panel a) and protein expression
(panel b and c) of the T1R2 (i) and T1R3 (ii) gene and protein in retinal
microvascular endothelial cells (RMVEC) and positive control lung
microvascular endothelial cells (LMVEC). siRNA knockdown of T1R2
and T1R3 was performed in RMVEC to validate expression. Gene and
protein expression is analysed relative to β-actin. A representative blot is
included for Western blotting (inset, panel b). Cell surface expression
(panel c) of T1R2 (i) and T1R3 (ii) was determined with whole cell
ELISA in retinal microvascular endothelial cells. n = 5. Data is
expressed as mean ± S.E.M. *p < 0.05 versus ns siRNA
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(Fig. 2a), the artificial sweetener was utilised at the concentra-
tion previously identified to be protective against endotoxin-
induced barrier disruption in the pulmonary endothelium
(0.1 mM) [12]. We next sought to establish whether sucralose
was protective against VEGF-induced permeability in the cell
model of the retinal endothelium. Exposure of RMVEC to
VEGF significantly decreased monolayer resistance and in-
creased permeability as measured by TER and FITC-dextran
permeability assay respectively (Fig. 2b); however, VEGF-
induced permeability was significantly attenuated by sucra-
lose (Fig. 2b (ii)). Whilst permeability is an indicator of non-
proliferative DR, a key pathophysiology of proliferative DR is
aberrant vasculogenesis of the retinal microvasculature [6].
Therefore, we next studied the effect of sucralose on
vasculogenic processes in the retinal endothelium. RMVEC
exposed to sucralose alone, in the absence of VEGF, exhibited
no change in cell proliferation, adhesion, migration or tube
formation (Fig. 2c–f). RMVEC exposed to VEGF displayed
a significant increase in proliferation, adhesion and migration,
which was blocked by sucralose (Fig. 2c–e). Likewise,
VEGF-induced tube formation and angiogenic potential, de-
noted as number of joints, in RMVEC was significantly
attenuated by exposure to sucralose (Fig. 2f). These studies
demonstrate that activation of the sweet taste receptors, T1R2
and T1R3, exerts a protective effect on the retinal endothelial
cell model, to blunt VEGF-induced vasculogenic processes.
Similar to VEGF, exposure of the endothelium to high glucose
concentrations has been demonstrated to increase
vasculogenic processes in the endothelium, linked to DR
[22]. Exposure of RMVEC to sucralose significantly reduced
high glucose-induced cell migration and proliferation (data
not shown), indicating a pan-protective role of sucralose on
the retinal endothelium.
Sucralose attenuates VEGF-induced vasculogenic
processes in retinal microvascular endothelial cells
through the sweet taste receptor T1R3
To study whether sucralose acts on retinal endothelial cells
through the sweet taste receptors, T1R2 and T1R3, the next
experiments were performed with inhibition of the sweet
taste receptors. Zinc sulphate, a chemical inhibitor of sweet
taste receptor activity, with no impact on sweet taste recep-
tor whole cell or cell surface expression (Fig. 3a, b) was
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Fig. 2 An agonist for sweet taste receptors T1R2 and T1R3, sucralose,
attenuates VEGF-induced angiogenic processes in the retinal
microvascular endothelium. Panel a: cell viability of RMVEC was
measured by CCK8 assay following exposure to sucralose (1 nM–
1 mM). Panel b–f: changes in retinal endothelial cell: monolayer
permeability (panel b), proliferation (panel c), adhesion (panel d),
migration (panel e), tube formation (panel f (ii)) and angiogenic
potential (panel f (iii)) were measured following exposure to sucralose
(0.1 mM) in the presence (closed bars) and absence (open bars) of VEGF
(100 ng/ml). Validation of FITC-dextran permeability assay is shown
using TER with VEGF (panel b (i)). A representative image of the
wound-healing assay (panel e (i)) and Matrigel™ assay (panel f (i)) is
shown. n = 5. Data is expressed as mean ± S.E.M. *p < 0.05 versus
vehicle for VEGF
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utilised [23, 24]. RMVEC were exposed to zinc sulphate in
the presence and absence of VEGF and sucralose and
vasculogenic processes were assessed. The protective ef-
fect of sucralose, in attenuating VEGF-induced permeabil-
ity and vasculogenic processes in RMVEC, was blunted by
zinc sulphate (Fig. 3d–h). Interestingly, in the absence of
VEGF, zinc sulphate had no impact on endothelial mono-
layer permeability (Fig. 3c); however, cell proliferation,
adhesion, migration, tube formation and angiogenic poten-
tial were all significantly increased by zinc sulphate
(Fig. 3d–h). These studies indicate that chemical inhibition
of T1R2 and T1R3 blocks the protective role of sucralose
in the retinal microvascular cell line. To establish the role
of each receptor in regulating this protective effect, we next
used siRNA to perform molecular inhibition of T1R2 and
T1R3. Knockdown of T1R2 or T1R3, confirmed by re-
duced mRNA and protein expression (Fig. 1), had no im-
pact on RMVEC viability compared to non-specific siRNA
control (Fig. 4a). Following knockdown of T1R2, sucra-
lose significantly reduced VEGF-induced permeability of
the retinal endothelial barrier, similar to the effect in cells
transfected with non-specific siRNA (Fig. 4b (i)).
Conversely, following molecular inhibition of T1R3 in
RMVEC, sucralose had no effect on VEGF-induced barrier
disruption (Fig. 4b (ii)). Likewise, sucralose significantly
attenuated VEGF-induced endothelial cell adhesion, migra-
tion and tube formation in RMVEC with T1R2, but not
T1R3, knockdown (Fig. 4c–e). These data demonstrate that
the protective role of sucralose, in blocking VEGF-
mediated vasculogenic processes in retinal endothelial
cells, is mediated through the sweet taste receptor, T1R3.
Sucralose attenuates VEGF-induced vasculogenic
processes in the retinal microvascular endothelial cell
line by inhibiting Akt activity
Finally, we sought to understand the mechanism through
which T1R3 regulates VEGF-mediated vasculogenic process-
es in the retinal microvasculature. VEGFR2 is a major regu-
lator of vasculogenesis [25, 26] therefore we studied whether
sucralose exerted a direct effect on expression of the receptor
at the cell surface. As previously described [27], RMVEC
exposed to VEGF displayed a significant decrease in
VEGFR2 expression at the cell surface (Fig. 5a).
Interestingly, VEGFR2 surface expression was not affected
by sucralose (Fig. 5a). VEGF-VEGFR2 binding triggers the
PI3K/Akt signalling pathway which plays a key role in
vasculogenic processes therefore we next sought to assess
whether sucralose exerts a protective role on the retinal endo-
thelium through Akt signalling [28, 29]. Activity of Akt1/2,
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Fig. 3 Inhibition of the sweet taste receptors T1R2 and T1R3, through
zinc sulphate, blocks the protective effect of sucralose on VEGF-induced
angiogenic processes in the retinal microvascular endothelium. Retinal
microvascular endothelial cells were exposed to the sweet taste receptor
inhibitor, zinc sulphate (0.7 mM), in the presence and absence of
sucralose (0.1 mM) and VEGF (100 ng/ml). Panel a: protein
expression of T1R2 (i) and T1R3 (ii) was assessed by Western blotting
of RMVEC lysates. Panel b: cell surface expression of T1R2 (i) and
T1R3 ( ii) was determined by whole cell ELISA in retinal
microvascular endothelial cells. Panel c–h: changes in retinal endothelial
cell: monolayer permeability (panel c), proliferation (panel d), adhesion
(panel e), migration (panel f), tube formation (panel g) and angiogenic
potential (panel h) were measured following exposure to sucralose
(0.1 mM) in the presence (closed bars) and absence (open bars) of
VEGF (100 ng/ml). n = 5. Data is expressed as mean ± S.E.M.
*p < 0.05 versus vehicle for VEGF, #p < 0.05 versus vehicle for zinc
sulphate
Graefes Arch Clin Exp Ophthalmol
assessed by Western blot analysis of serine 473 [28], was
significantly increased in RMVEC exposed to VEGF
(Fig. 5b). Interestingly, sucralose had no effect on Akt activity
in the absence of VEGF but the sweetener attenuated VEGF-
induced Akt phosphorylation (Fig. 5b). To establish whether
sucralose protects against VEGF-mediated vasculogenesis
through inhibition of Akt, RMVEC were exposed to the Akt
activator, SC79, in the presence and absence of VEGF and
sucralose. SC79 alone significantly increased cell adhesion,
migration and tube formation in retinal endothelial cells
(Fig. 5c–e). Following exposure to SC79, VEGF significantly
increased permeability (Supplementary Table 1) and
vasculogenic processes in RMVEC in the presence of sucra-
lose (Fig. 5c–e). Activation of Akt was thus able to block the
protective effect of sucralose and restore VEGF-induced
vasculogenesis in the cell model of the retinal endothelium.
Taken together, these date demonstrate that activation of the
sweet taste receptor, T1R3, by the artificial sweetener sucralose,
protects a retinal microvascular endothelial cell line against
VEGF-induced vasculogenesis. We further show that sucralose
exerts this protective effect by blocking Akt activation, indicat-
ing that the T1R3 represents a novel potential therapeutic target
for reducing vascular permeability and vasculogenesis in
patients with non-proliferative and proliferative DR.
Discussion
In this study, we present findings which demonstrate, for the
first time, the expression of sweet taste receptors T1R2 and
T1R3 in a cell model of the human retinal microvascular en-
dothelium. Our research identifies a role for sweet taste sens-
ing in regulating the retinal endothelium; activation of the
sweet taste receptor with sucralose protects the retinal endo-
thelium against VEGF-induced permeability and VEGF-
induced vasculogenic processes, linked to non-proliferative
and proliferative DR respectively. We further demonstrate that
the protective effect of sucralose is mediated through the re-
ceptor T1R3, and not T1R2, and by blunting VEGF-induced
Akt activity in retinal endothelial cells. Findings from the
study demonstrate a novel mechanism through which the ret-
inal endothelium is regulated and indicate a potential therapeu-
tic intervention to reduce the aberrant retinal vasculogenesis
observed in patients with DR.
Hyperglycaemia in diabetes is associated with the aberrant
vasculogenesis observed in patients with DR [2]. It may there-
fore appear counter-intuitive for a sweet taste receptor to exert
a protective effect on the endothelium; however, glucose con-
centrations of ~ 300 mM are needed to stimulate T1R2 and
T1R3, concentrations which are not physiological in the
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Fig. 4 Inhibition of T1R3, but not T1R2, blocks the protective effect of
sucralose on VEGF-induced angiogenesis in the retinal microvascular
endothelium. RMVEC were transiently transfected with T1R2 or T1R3
siRNA, or a non-specific scrambled siRNA (ns) for 24 h prior to
treatment with sucralose (0.1 mM) and VEGF (100 ng/ml). Panel a:
cell viability of RMVEC was measured by CCK8 assay following
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endothelial cell monolayer permeability were determined using the
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(ii) siRNA knockdown. Panel c–e: changes in retinal endothelial cell:
adhesion (panel c), migration (panel d), tube formation (panel e) were
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circulation [30]. In contrast, sucralose, like many artificial
sweeteners, stimulates the sweet taste receptor at low concen-
trations (< 1 mM) [14]. Consumption of artificial sweeteners
has increased in the last 15 years with 62% of all soft drinks
consumed being sweetened by these non-nutritive sweeteners
[31]. In addition to being recommended for patients with dia-
betes to reduce intake of sugar, artificial sweeteners are also
used as an aid in weight-loss/management. There has, howev-
er, been significant controversy in recent years surrounding
the use of artificial sweeteners in the diet with both positive
and negative impacts on appetite, hunger, weight gain and
predisposition for glucose intolerance. As such, the majority
of these studies have focused on the small intestine environ-
ment, gut microbiota and incretin signalling. These studies
suggest increased sweeteners in the diet correlate with weight
gain and incidence of diabetes [32]. Following consumption
in the diet, a significant proportion of artificial sweetener is
absorbed by the small intestine into the systemic circulation
and, with the exception of aspartame, is excreted in a largely
unmetabolised form [33, 34]. However, there is still a limited
understanding of the physiological relevance of T1R2 and
T1R3 in the vasculature, and the resulting impact of sweet-
eners once they are in the circulation.
The blood-retinal barrier forms a selectively-permeable fil-
ter maintained by junctional complexes in retinal endothelial
cells to form the inner barrier [35]. The pathophysiology of
DR is based on multiple components, such as loss of pericyte
function and release of inflammatory cytokines by the retinal
pigmented epithelium; however, permeability of the retinal
endothelial monolayer, via elevated VEGF signalling, is a
key pathophysiology of macula edema observed in patients
with non-proliferative DR [2, 4]. We have previously demon-
strated a role for sweet taste sensing in reducing vascular leak
in the lung microvasculature linked to endotoxin-induced pul-
monary edema [12]. In the present study, we observe that
activation of T1R3, with the artificial sweetener sucralose,
exerts a similar effect in protecting the human retinal endothe-
lial monolayer from VEGF-induced permeability. These find-
ings therefore demonstrate a pan-protective role of the recep-
tor which is irrespective of injury stimulus or vascular bed.
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Fig. 5 Sucralose regulates VEGF-induced angiogenesis in the retinal
endothelium through suppressing Akt activity. Panel a and b: RMVEC
were exposed to sucralose (0.1 mM) in the presence and absence of
VEGF (100 ng/ml). VEGFR2 cell surface expression (panel a) and Akt
phosphorylation (panel b) were measured using whole-cell ELISA and
Western blotting respectively. A representative blot is shown. Panel c–e:
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measured following exposure to sucralose (0.1 mM) in the presence
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Data is expressed as mean ± S.E.M. *p < 0.05 versus vehicle for VEGF,
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Whilst these studies indicate the protective effect of a T1R3
agonist in a human cell model of the retinal microvasculature,
further studies are needed to confirm the physiological rele-
vance of these findings in vivo.
In patients with proliferative DR, aberrant vasculogenic
processes such as hyperproliferation and excessive neovascu-
larisation, are observed which are, in part, mediated through
pro-angiogenic VEGF signals [5–8]. We and others have pre-
viously demonstrated a close association between mecha-
nisms which regulate permeability of the endothelial barrier
and vasculogenic processes [16, 19, 20]. Therefore, in the
present study, we assessed the effect of T1R3 stimulation on
vasculogenic processes in a cell model of the retinal endothe-
liums, such as proliferation and tube formation. Activation of
the sweet taste receptor by sucralose exerted a protective effect
on VEGF-mediated vasculogenic processes such as excessive
proliferation, adhesion, migration and tube formation.
Interestingly, this protection was mediated through the sweet
taste receptor T1R3 rather than T1R2. Whilst the sweet taste
receptor is typically considered to be a heterodimer of
T1R2/T1R3, Nelson et al. have previously demonstrated that
T1R3, but not T1R2, can form a homodimer for sweet taste
sensing [13, 14]. It is therefore likely that sucralose binds to
the T1R3 homodimer to protect the retinal vasculature against
VEGF-induced vasculogenesis. Given that human retinal mi-
crovascular endothelial cells express T1R2 mRNA and pro-
tein at levels similar to T1R3, yet T1R2 is not involved in
permeability or vasculogenesis, this raises interesting ques-
tions regarding the potential role for this GPCR in the
microvasculature.
Akt has been implicated as a key signalling molecule
through which VEGF regulates vasculogenic processes [36].
VEGF-VEGFR2 binding results in PI3K-dependent phosphor-
ylation and activation of Akt resulting in increased endothelial
cell proliferation, migration and permeability [37].
Interestingly, artificial sweeteners have been demonstrated to
have opposing effects on Akt phosphorylation, depending on
the differentiation stage of the cell and the phosphorylation site
investigated [38, 39]. In the present study, we demonstrated
that sucralose blocked VEGF-induced phosphorylation of
Akt at Ser473. Given the role of Akt phosphorylation at this
residue in regulating FOXO1 target genes associated with
vasculogenesis [40, 41], our data indicates that T1R3 activation
blocks vasculogenic processes through Akt dephosphorylation.
Indeed, we observed that chemical activation of Akt reversed
the protective effects of sucralose on vasculogenesis. Sucralose
had no impact on Akt phosphorylation, or vasculogenic pro-
cesses, in the healthy endothelium (in the absence of VEGF).
Therefore it is possible that T1R3 signalling downregulates a
specific kinase which is upregulated by VEGF signalling, such
as mTOR [37]; however, further studies are needed to fully
understand the molecular mechanism through which T1R3
regulates Akt activity in the retinal endothelium.
At present, treatment for patients with non-proliferative
and proliferative DR is based on intravitreous injection of
anti-VEGF agents, such as ranibizumab, and panretinal laser
photocoagulation therapy [42]. Whilst these treatments are
effective in reducing retinopathy in patients, long-term use
of anti-VEGF agents has been linked to eye inflammation
and capillary regression of the remaining healthy microvas-
culature [43] Given the increasing number of patient with
diabetes, and the high chance of these patients developing
retinopathy [1, 2], there is a significant need to consider
alternate potential therapeutic approaches to reduce perme-
ability and vasculogenesis in the retinal microvasculature. In
the present study, we demonstrate that sucralose blocks
VEGF-induced permeability and vasculogenic processes.
Interestingly, in the healthy endothelium, in the absence of
VEGF, we demonstrate that sucralose has no effect on per-
meability or vasculogenesis. Our studies therefore indicate
that T1R3 represents a novel therapeutic target with potential
to reduce permeability and vasculogenesis in the retinal en-
dothelium in patients with both proliferative and non-
proliferative DR. Further research is needed to understand
the physiological effect of sweeteners on pathogenic events
leading to retinopathy, as well as the potential side effects of
sweeteners in the vasculature, similar to those seen with cur-
rent anti-VEGF treatment.
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